Health Condition 1: null- Patients undergoing CABG or valve or combined CABG and Valve surgery
Conditions
Interventions
Intervention1: Vitamin C 500 mg and Vitamin e 600 mg: At -36hr,-24 hr, -12 hr, +12hr, + 24 hr,+36 hr adn +48 hr
Control Intervention1: Placebo: 1 tab at -36hr,-24 hr, -12 hr, +12hr, + 24 hr,+36 hr adn
Sponsors
PGIMER CHANDIGARH
Eligibility
Inclusion criteria
Inclusion criteria: • Age over 18 years and less than 75 years • Patients undergoing CABG or valve or combined CABG and Valve surgery • Willing to provide informed consent for participations
Exclusion criteria
Exclusion criteria: • End stage renal disease, or CKD stage 5 (GFR • Ongoing infection by positive blood, urine or sputum cultures • Pregnant or lactating females • Advanced liver disease (cirrhosis, ascitis, jaundice) • Evidence of acute kidney injury prior to surgery • Neurologic signs or symptoms or history of increased intracranial pressures • Current participation in another interventional research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak serum creatinine levelTimepoint: Baseline, 24 hr ,48hr and 5 post operative day | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of AKI as defined by AKIN criteria s 2. Plasma NGAL and urinary IL-18 levels at randomization and 12 hr post surgery 3. Plasma markers of oxidative stress at randomization and 12 hr post surgery 5. Clinical Outcomes: Duration of hospital stay, All cause mortality, Requirement of renal replacement therapy Timepoint: Baseline , 12hr 24 hr 48 hr 5th surgery day after | — |
Countries
India
Contacts
Public ContactInderjeet Singh
PGIMER CHANDIGARH
Outcome results
None listed